Sugi Predict

Sugi Predict / Targets / MAP3K5

MAP3K5

Mitogen-activated protein kinase kinase kinase 5 · Q99683 · MAP3K5 on Sugi Atlas →

36,140 patent compounds predicted against MAP3K5, 21,161 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL233100 SCHEMBL233100 0.84 20/20
SCHEMBL233101 SCHEMBL233101 0.84 20/20
SCHEMBL234485 SCHEMBL234485 0.81 20/20
SCHEMBL233558 SCHEMBL233558 0.74 20/20
SCHEMBL233559 SCHEMBL233559 0.74 20/20
SCHEMBL232980 SCHEMBL232980 0.74 20/20
SCHEMBL231900 SCHEMBL231900 0.71 20/20
SCHEMBL233083 SCHEMBL233083 0.69 20/20
SCHEMBL231878 SCHEMBL231878 0.68 20/20
SCHEMBL231879 SCHEMBL231879 0.68 20/20
SCHEMBL231864 SCHEMBL231864 0.67 20/20
SCHEMBL232857 SCHEMBL232857 0.67 20/20
SCHEMBL232858 SCHEMBL232858 0.67 20/20
SCHEMBL232558 SCHEMBL232558 0.66 20/20
SCHEMBL232559 SCHEMBL232559 0.66 20/20
SCHEMBL233189 SCHEMBL233189 0.66 20/20
SCHEMBL231489 SCHEMBL231489 0.65 20/20
SCHEMBL231490 SCHEMBL231490 0.65 20/20
SCHEMBL232907 SCHEMBL232907 0.64 20/20
SCHEMBL230917 SCHEMBL230917 0.63 20/20

Clinical trials — most relevant to MAP3K5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer PHASE3RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... PHASE2COMPLETED
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE2COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Histiocytic Disorder Follow-up Study nanRECRUITING
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP3K5 binder may also engage these)

ProteinNameSimilarity
O35099 — 1.000 O35099 →
A2AQW0 — 0.993 A2AQW0 →
MAP3K15 Mitogen-activated protein kinase kinase kinase 15 0.992 landscape →
TBK1 Serine/threonine-protein kinase TBK1 0.986 landscape →
Q21029 — 0.985 Q21029 →
Q9BXB4 — 0.984 Q9BXB4 →
P62205 — 0.983 P62205 →
Q921C3 — 0.983 Q921C3 →
Q9UPM8 — 0.983 Q9UPM8 →
Q6DD21 — 0.983 Q6DD21 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.983 landscape →
Q8CI95 — 0.982 Q8CI95 →
Q07139 — 0.982 Q07139 →
Q5XI81 — 0.982 Q5XI81 →
Q9UPW5 — 0.982 Q9UPW5 →
Q6GLC9 — 0.980 Q6GLC9 →
Q95JW3 — 0.980 Q95JW3 →
Q8NHP6 — 0.980 Q8NHP6 →
F4JSE7 — 0.980 F4JSE7 →
F4IVI0 — 0.980 F4IVI0 →
Q3B7T1 — 0.980 Q3B7T1 →
Q641K1 — 0.980 Q641K1 →
DNAJC13 DnaJ homolog subfamily C member 13 0.980 landscape →
Q8BPM2 — 0.980 Q8BPM2 →
Q6DDI6 — 0.980 Q6DDI6 →
Q28GW8 — 0.980 Q28GW8 →
EEF2K Eukaryotic elongation factor 2 kinase 0.980 landscape →
E9Q4Z2 — 0.979 E9Q4Z2 →
Q24498 — 0.979 Q24498 →
Q5ZKK7 — 0.979 Q5ZKK7 →